We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+27.43%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$197M
AUM Growth
-$76M
Cap. Flow
-$97.6M
Cap. Flow %
-49.58%
Top 10 Hldgs %
44.5%
Holding
160
New
26
Increased
14
Reduced
15
Closed
66

Top Buys

Rank Stock Value
1
ATXS
Astria Therapeutics
ATXS
+$9.39M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$4.07M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$3.73M
4
OTLK icon
Outlook Therapeutics
OTLK
+$3.62M
5
REPL icon
Replimune Group
REPL
+$3.32M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$8.27M
2
INSM icon
Insmed
INSM
+$5.77M
3
MBTC
Nocturne Acquisition Corporation Ordinary Shares
MBTC
+$5.17M
4
BCAB icon
BioAtla
BCAB
+$4.26M
5
ILMN icon
Illumina
ILMN
+$4.2M

Sector Composition

Rank Sector Weight
1 Healthcare 88.67%
2 Financials 5.8%
3 Communication Services 0.42%
4 Industrials 0.36%
5 Materials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVRO
26
DELISTED
NEVRO CORP.
NVRO
$3.01M 1.53%
76,000
+12,000
+19% +$499K
PACB icon
27
Pacific Biosciences
PACB
$363M
$2.99M 1.52%
+365,000
New +$3.14M
BHVN icon
28
Biohaven
BHVN
$2.17B
$2.78M 1.41%
+200,000
New +$2.82M
CTIC
29
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$2.7M 1.37%
450,000
+23,000
+5% +$126K
SIBN icon
30
SI-BONE Inc
SIBN
$813M
$2.65M 1.35%
195,000
+28,000
+17% +$408K
NEO icon
31
NeoGenomics
NEO
$2B
$2.63M 1.34%
+285,000
New +$2.66M
TVRD
32
Tvardi Therapeutics
TVRD
$23.1M
$2.1M 1.07%
5,443
+82
+2% +$31.1K
NBIX icon
33
Neurocrine Biosciences
NBIX
$16.2B
$2.09M 1.06%
17,500
-1,500
-8% -$176K
COLL icon
34
Collegium Pharmaceutical
COLL
$944M
$2.09M 1.06%
90,000
-26,000
-22% -$524K
PCVX icon
35
Vaxcyte
PCVX
$8.5B
$2.06M 1.05%
+43,000
New +$1.69M
TGVCU
36
DELISTED
TG Venture Acquisition Corp. Units
TGVCU
$2.04M 1.04%
200,000
– –
PLRX icon
37
Pliant Therapeutics
PLRX
$65M
$1.93M 0.98%
100,000
-115,000
-53% -$2.4M
SAGE
38
DELISTED
Sage Therapeutics
SAGE
$1.91M 0.97%
+50,000
New +$1.91M
BLRX
39
BioLineRX
BLRX
$12.1M
$1.83M 0.93%
77,591
-26,141
-25% -$778K
ADRT
40
DELISTED
Ault Disruptive Technologies Corporation
ADRT
$1.54M 0.78%
150,000
– –
TGTX icon
41
CALL
TG Therapeutics
TGTX
$7.59B
$1.18M 0.6%
+100,000
New +$726K
SYRS
42
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.13M 0.57%
+315,070
New +$1.37M
WAVSU
43
DELISTED
Western Acquisition Ventures Corp. Unit
WAVSU
$1.1M 0.56%
100,000
– –
MURFU
44
DELISTED
Murphy Canyon Acquisition Corp. Unit
MURFU
$1.02M 0.52%
100,000
– –
ARYD
45
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.01M 0.51%
100,000
– –
MITA
46
DELISTED
Coliseum Acquisition Corp. Class A Ordinary Share
MITA
$853K 0.43%
85,000
– –
TSHA icon
47
Taysha Gene Therapies
TSHA
$1.82B
$811K 0.41%
+359,051
New +$727K
SLGC
48
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$778K 0.4%
+310,000
New +$865K
HYRE
49
DELISTED
HyreCar Inc. Common Stock
HYRE
$716K 0.36%
+1,688,120
New +$1.07M
TERN
50
DELISTED
Terns Pharmaceuticals
TERN
$713K 0.36%
+70,000
New +$466K
1
2
3 4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return

Altium Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Altium Capital Management held 160 positions worth $197M, down 28% from $273M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Altium Capital Management withdrew a net $97.6M in Q4 2022, closing 66 positions and reducing 15 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $8.27M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 79% a quarter earlier, followed by Financials and Communication Services.

Against the trend, Altium Capital Management opened a new position in Tandem Diabetes Care worth $4.05M.

  • Altium Capital Management's largest Q4 2022 buy was Tandem Diabetes Care: 90,000 shares worth $4.05M.
  • Altium Capital Management added most to Astria Therapeutics in Q4 2022, an estimated $9.39M increase.
  • Altium Capital Management's biggest Q4 2022 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $3.1M.
  • Altium Capital Management fully exited ChemoCentryx, Inc. in Q4 2022, selling an estimated $8.27M.
  • Altium Capital Management's ten largest holdings make up 45% of its $197M portfolio in Q4 2022.
  • Altium Capital Management opened 26 new positions and closed 66 in Q4 2022.
  • Altium Capital Management's portfolio value fell 28% quarter-over-quarter to $197M.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.